News. 28/04/22

Procuritas partners with Nordic Biomarker

Procuritas Capital Investors (“Procuritas”) is pleased to announce that it has taken a majority stake in Nordic Biomarker, a fast-growing Swedish supplier of advanced reagents for IVD coagulation analyzers with a clear sustainability-driven purpose.  

Nordic Biomarker was founded in 2007 to meet market demand for an independent OEM-supplier of high-quality reagents for coagulation analyzers. The company has a growing product portfolio of routine and specialty reagents for IVD coagulation testing. In 2017, Nordic Biomarker teamed up with Medirox, adding CE-marked reagent kits to the product offering. Products are delivered to clients around the world for sale under their own brand names as well as to distributors of its portfolio of Medirox branded kits. Production is performed in-house at Nordic Biomarker’s new facilities in Umeå and in Linköping, Sweden. Nordic Biomarker is investing significantly in research and development of new products and has several new products in pipeline. The company had revenue of 131M SEK in 2021 and has approximately 80 employees. 

Procuritas has a strong track record of investing in companies that have the potential for transformational growth, in this instance to grow from a niche leader to a global challenger in coagulation testing through organic growth as well as M&A. The investment in Nordic Biomarker aligns with Procuritas’ target to support the UN Sustainable Development Goals and fits in with #3 “To ensure healthy lives and promote well-being at all ages”.  

Rikard Rodén, CEO, commented: “We are really proud to be partnering with Procuritas who have a fantastic track record of supporting businesses on their growth journey and making sure their potential is realized.  We have built up a great partnership over the past months and really look forward to working together.” 

Johan Conradsson, Co-Managing Partner at Procuritas, commented: “With our ageing population and the trend towards science-based health testing, we see great opportunities for Nordic Biomarker to continue its impressive journey. The company has high-quality products for patients and holds a unique and competitive position in a growing market. We see a great future for this business.”

For further information, please contact:

Johan Conradsson

About Procuritas
Procuritas is a mid-market Nordic private equity investor, building up niche market-leading companies through transformative growth in service industry consolidations, digital consumer businesses, software and select industrial sectors.  As the longest-established private equity firm in the Nordics with a 35-year track record, Procuritas has carefully invested in more than 45 companies, accelerated their growth and helped them to realize their true business potential. The long-serving team is characterized by its passion for business, hands-on experience, enthusiasm, commitment to ESG-linked value creation initiatives and strong belief that they are allies in the quest to build strong and sustainable businesses.  Read more at  

About Nordic Biomarker
Nordic Biomarker is a Swedish original manufacturer of advanced reagents, calibrators and controls for coagulation analyzers and offers products used for a wide range of routine and specialty tests. The company’s expertise covers all relevant technology areas, and prides itself on being experts when it comes to both immunological, chromogenic as well as clotting assays. Read more at 


More news.


Strandberg Guitars appoints Mikaela Jansson as new CEO

Founder Ola Strandberg continues as Chief Creative Officer Strandberg Guitars is the worldwide market leader in headless guitars, under the .strandberg* brand. Today, Strandberg Guitars announced that Mikaela Jansson has been appointed CEO of the company. Former CEO and Founder Ola Strandberg will, as planned, take on the role as Chief Creative Officer and continue...


Procuritas’s Medtanken platform partners with regional leader HMC and expands to Region Skåne

Procuritas Capital Investors VI (“Procuritas”), the mid-market Nordic private equity investor, announces that its portfolio company Medtanken, a leading primary care group in Western Sweden, has entered into Region Skåne through the partnership with Hälsomedicinskt center i Sverige AB (“HMC”), a fast-growing primary care provider in the region. With its passion for building strong sustainable...


Procuritas partners with We Select

Procuritas Capital Investors (“Procuritas”) is pleased to announce that it has acquired a majority stake in We Select, a fast-growing digital talent acquisition platform on social media. Key management will retain significant ownership of the company after the transaction. We Select was founded in 2011 as a traditional recruitment services company. After launching its digital...